SynAct Pharma AB (CHIX:SYNACS) Accounts Payable: kr1.66 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:SYNACS SynAct Pharma AB CHIX:SYNACS
9 GF Score
Price kr18.62
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB Accounts Payable?

SynAct Pharma AB CHIX:SYNACS 9 Accounts Payable is kr1.66 Mil as of Jun. 2026. GuruFocus rates CHIX:SYNACS with a GF Score™ of 9/100. The stock has 1 warning sign investors should review.

SynAct Pharma AB's Accounts Payable for the quarter that ended in Jun. 2026 was kr1.66 Mil.

SynAct Pharma AB's quarterly Accounts Payable declined from Dec. 2025 (kr9.49 Mil) to Mar. 2026 (kr6.56 Mil) and declined from Mar. 2026 (kr6.56 Mil) to Jun. 2026 (kr1.66 Mil).

SynAct Pharma AB's annual Accounts Payable increased from Dec. 2023 (kr9.67 Mil) to Dec. 2024 (kr17.35 Mil) but then declined from Dec. 2024 (kr17.35 Mil) to Dec. 2025 (kr9.49 Mil).

SynAct Pharma AB Accounts Payable Related Terms

SynAct Pharma AB Accounts Payable Historical Data

* Premium members only.

The historical data trend for SynAct Pharma AB's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynAct Pharma AB Accounts Payable Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.25 4.72 9.67 17.35 9.49

SynAct Pharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.42 9.66 9.49 6.56 1.66
CHIX:SYNACS
9GF Score
SynAct Pharma AB CHIX:SYNACS
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of kr1.66 Mil mean?
SynAct Pharma AB (CHIX:SYNACS) has a Accounts Payable of kr1.66 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on SynAct Pharma AB and its competitors.
Is SynAct Pharma AB's Accounts Payable too high?
SynAct Pharma AB's current Accounts Payable is kr1.66 Mil. Overall, SynAct Pharma AB has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's Accounts Payable compare to VRTX and REGN?
SynAct Pharma AB's Accounts Payable of kr1.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on SynAct Pharma AB and its competitors. SynAct Pharma AB's current Accounts Payable is kr1.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (CHIX:SYNACS) has a current Accounts Payable of kr1.66 Mil. The current Accounts Payable is kr1.66 Mil. SynAct Pharma AB's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For SynAct Pharma AB (CHIX:SYNACS), the current Accounts Payable is kr1.66 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SynAct Pharma AB Business Description

Other Exchanges SYNACT:Sweden8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
9GF Score

Get the complete analysis for CHIX:SYNACS

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr18.62
Price